📌 Key Takeaways
- Topic: Quartz Sand for Photovoltaic: High Purity Requirements for Solar Crucibles
- Keywords: Solvay Zeosil
- Published: 2026-11-20 02:33:44
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica for Wafer Polishing: Slurry Types, Particle Size and Performance
- Silica Free Flow Agent: Typical Dosage, Benefits and Best Grades
- Silica Polishing Slurry: How It Works, Particle Sizes and Applications
- Lee, X. Y., Chew, T. L., Oh, P. C., Jawad, Z. A. & Ho, C.-D. CO 2 adsorption of MSU-2 synthesized by using nonionic polyethyleneoxide (PEO)-based surfactants. Chem. Eng. Commun. 208, 474-482 (2021). Piece CAS Google Scholar
- Fused Silica CAS 60676-86-0: Identification, Properties and Safety Data
- What Is Silica Fume? Properties, Specifications and Uses in High-Performance Concrete
- Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
Silica and Sodium Hydroxide Reaction: Equation, Products and Applications
What is silica (SiO₂)?
colloidal silica slurry The unique properties of MSNs make it greatly superior for the construction of multifunctional nanocomposites and drug delivery system. Different therapeutic nanoplatforms obtained through the careful design of MSNs have revealed promising potential in the field of targeted disease therapy. Current applications of MSNs include tumor therapy, 367, 368, 369 anti-infection therapy (bacteria and virus), 370, 371, 372, 373 anti-oxidant/anti-inflammatory therapy (Alzheimer's disease, acute kidney injury, etc.), 374, 375, 376 and metabolic diseases treatment (diabetes, osteoporosis, fatty liver, etc) 377, 378, 379, 380 (Fig. 7 ). In general, the targeted therapeutic characteristics of MSNs can be reflected in the following aspects: (1) Loading chemotherapy drugs or other drugs with toxic side influences, so that they can be released in a controlled manner by MSNs at the targeted sites to prevent their premature release. (2) Selective enrichment at the lesion sites through passive targeting or active targeting, resulting in the higher therapeutic efficacy. (3) Use the MSNs matrix to develop a non-invasive, spatial and temporal controllable targeted therapeutic plan, consequently to overcome the limitations and defects of conventional clinical treatment modalities. To date, the emerging targeted therapeutic modalities developed based on MSNs include dynamic therapy such as photodynamic, sonodynamic and chemodynamic therapies, thermal ablation therapy such as photothermal therapy and magnetic thermotherapy, enzyme-like catalytic therapy, immunotherapy, gene therapy, and others. Meanwhile, the integration of various therapeutic modalities on a single MSNs is expected to enhance the therapeutic efficacy synergistically (Fig. 7 ). In this part, we will discuss MSNs-based therapeutic modalities.
What is the difference between fumed silica and precipitated silica?
silicon oxide Huang, F. et al. An acid-responsive microfluidic salmonella biosensor using curcumin as signal reporter and ZnO-capped mesoporous silica nanoparticles for signal amplification. Sens. Actuators, B 312, 127958 (2020). Article CAS Google Scholar
What drives silica raw material prices?
porous silica
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.